- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting angiogenesis in oncology, ophthalmology and beyond
Authors
Keywords
-
Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 22, Issue 6, Pages 476-495
Publisher
Springer Science and Business Media LLC
Online
2023-04-11
DOI
10.1038/s41573-023-00671-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiangiogenesis: Vessel Regression, Vessel Normalization, or Both?
- (2022) Hellmut G. Augustin et al. CANCER RESEARCH
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- (2022) Jeffrey S Heier et al. LANCET
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
- (2022) Niharika B. Mettu et al. JAMA Network Open
- Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar
- (2022) Eunji Kim et al. Ophthalmology and Therapy
- INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA
- (2022) David M. Brown et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
- (2022) Colin S Tan et al. Clinical Ophthalmology
- Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
- (2022) Sonia A. Patel et al. CLINICAL CANCER RESEARCH
- TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2022) Kristina W. Thiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular senescence and senolytics: the path to the clinic
- (2022) Selim Chaib et al. NATURE MEDICINE
- Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
- (2022) Tao Ouyang et al. Frontiers in Oncology
- Dostarlimab: A Review
- (2022) Bárbara Costa et al. Biomolecules
- Endothelial cell diversity: the many facets of the crystal
- (2022) Lorena Perez‐Gutierrez et al. FEBS Journal
- Faricimab: an investigational agent targeting the Tie-2/Angiopoietin pathway and VEGF-A for the treatment of retinal diseases
- (2021) Massimo Nicolò et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition
- (2021) Sergio Crespo-Garcia et al. Cell Metabolism
- Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non-clear cell renal cell carcinoma
- (2021) Andrew J Armstrong et al. CLINICAL CANCER RESEARCH
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy
- (2021) Marlena Brzozowa-Zasada European Surgery-Acta Chirurgica Austriaca
- Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
- (2021) Claire M. Gelfman et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
- (2021) Toni K. Choueiri et al. NATURE MEDICINE
- Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
- (2021) Josh O. Wallsh et al. Cells
- Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer
- (2021) Kabir A Khan et al. EMBO Molecular Medicine
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
- (2021) Mark A. Socinski et al. Journal of Thoracic Oncology
- A Long‐Term Extension Study of Bevacizumab in Patients With Solid Tumors
- (2021) Amit M. Oza et al. ONCOLOGIST
- Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
- (2021) Rehan M Hussain et al. Drug Design Development and Therapy
- VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
- (2021) Evripidis Lanitis et al. Journal for ImmunoTherapy of Cancer
- An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
- (2021) Yukari Shirai et al. Cancers
- Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
- (2021) Andrew B. Nixon et al. CLINICAL CANCER RESEARCH
- Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
- (2021) Andrew B. Nixon et al. CLINICAL CANCER RESEARCH
- Belzutifan: First Approval
- (2021) Emma D. Deeks DRUGS
- LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy
- (2021) Pin Li et al. EMBO Molecular Medicine
- Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration
- (2021) Arshad M. Khanani et al. JAMA Ophthalmology
- Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study
- (2021) Victor H. Gonzalez et al. Translational Vision Science & Technology
- 354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
- (2021) Vicky Makker et al. Journal for ImmunoTherapy of Cancer
- FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
- (2021) Angela Damato et al. Frontiers in Oncology
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- (2021) Nancy M. Holekamp et al. OPHTHALMOLOGY
- Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
- (2020) Angeles Alvarez Secord et al. CLINICAL CANCER RESEARCH
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
- (2020) John D. Martin et al. Nature Reviews Clinical Oncology
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
- (2020) Sumanta K. Pal et al. BJU INTERNATIONAL
- Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema
- (2020) Lincoln T. Shaw et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy
- (2020) Irene Tom et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design
- (2020) Kaitlyn Sadtler et al. ADVANCED DRUG DELIVERY REVIEWS
- APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
- (2020) Michael N. Cohen et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
- (2020) Robert P. Finger et al. BMC Ophthalmology
- FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
- (2020) Jae Hong Im et al. Nature Communications
- TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
- (2020) Laurence Albiges et al. ANNALS OF ONCOLOGY
- Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- (2020) Won Suk Lee et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer
- (2020) Yoshiro Itatani et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways
- (2020) Cuiling Zhong et al. Nature Communications
- Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer
- (2020) Ye Zeng et al. Frontiers in Cell and Developmental Biology
- Long-acting intraocular delivery strategies for biological therapy of age-related macular degeneration
- (2019) Shwetha Iyer et al. JOURNAL OF CONTROLLED RELEASE
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adeno-associated virus vector as a platform for gene therapy delivery
- (2019) Dan Wang et al. NATURE REVIEWS DRUG DISCOVERY
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- The Placental Growth Factor Pathway and Its Potential Role in Macular Degenerative Disease
- (2019) Fiona Cunningham et al. CURRENT EYE RESEARCH
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- (2019) Pravin U. Dugel et al. OPHTHALMOLOGY
- Adipocyte and lipid metabolism in cancer drug resistance
- (2019) Yihai Cao JOURNAL OF CLINICAL INVESTIGATION
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- (2019) Laurence Albiges et al. EUROPEAN UROLOGY
- Abicipar pegol—a novel anti-VEGF therapy with a long duration of action
- (2019) Elad Moisseiev et al. EYE
- The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
- (2019) Johanna C. Bendell et al. ONCOLOGIST
- The tumor vasculature an attractive CAR T cell target in solid tumors
- (2019) Parvin Akbari et al. ANGIOGENESIS
- Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy – a systematic approach to identify and characterize data sources
- (2019) Vincent Daien et al. BMC Ophthalmology
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
- (2018) Hideki Iwamoto et al. Cell Metabolism
- Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
- (2018) Yoshiro Itatani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning
- (2018) Takahiro Seki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
- (2018) Yuanyuan Liu et al. MOLECULAR THERAPY
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Cell Metabolism
- (2018) Guy Eelen et al. PHYSIOLOGICAL REVIEWS
- Choriocapillaris Loss in Advanced Age-Related Macular Degeneration
- (2018) Carlos A. Moreira-Neto et al. Journal of Ophthalmology
- Anti-Angiogenics: Current Situation and Future Perspectives
- (2018) Katja Zirlik et al. Oncology Research and Treatment
- Progression of Geographic Atrophy in Age-related Macular Degeneration
- (2018) Tiarnan D. Keenan et al. OPHTHALMOLOGY
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
- (2017) Sobha Sivaprasad et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology
- (2017) Hellmut G. Augustin et al. SCIENCE
- A miR-327–FGF10–FGFR2-mediated autocrine signaling mechanism controls white fat browning
- (2017) Carina Fischer et al. Nature Communications
- Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors
- (2017) Szilvia Torok et al. Theranostics
- Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
- (2017) Filipe Mira et al. Journal of Ophthalmology
- Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
- (2017) Carlos Bais et al. JNCI-Journal of the National Cancer Institute
- An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications
- (2017) Evan N. Dunn et al. Ophthalmic Surgery Lasers & Imaging Retina
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
- (2016) Sophia Frentzas et al. NATURE MEDICINE
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
- (2016) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
- (2016) Maureen G. Maguire et al. OPHTHALMOLOGY
- Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
- (2016) Yin Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat
- (2016) Takahiro Seki et al. Nature Communications
- Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- (2016) Yunlong Yang et al. Nature Communications
- Defining response to anti-VEGF therapies in neovascular AMD
- (2015) W M Amoaku et al. EYE
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
- (2015) Lars G Fritsche et al. NATURE GENETICS
- Treatment Choice for Diabetic Macular Edema
- (2015) Daniel F. Martin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2015) David M. Brown et al. OPHTHALMOLOGY
- Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion
- (2015) Peter A. Campochiaro et al. OPHTHALMOLOGY
- Molecular pathogenesis of retinal and choroidal vascular diseases
- (2015) Peter A. Campochiaro PROGRESS IN RETINAL AND EYE RESEARCH
- Immune mechanisms in inflammatory and degenerative eye disease
- (2015) Victor L. Perez et al. TRENDS IN IMMUNOLOGY
- Endothelial destabilization by angiopoietin-2 via integrin β1 activation
- (2015) Laura Hakanpaa et al. Nature Communications
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
- (2014) D. C. Smith et al. CLINICAL CANCER RESEARCH
- A review of anti-VEGF agents for proliferative diabetic retinopathy
- (2014) P Osaadon et al. EYE
- Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
- (2014) S. Ramakrishnan et al. Journal of Neuroimmune Pharmacology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
- (2014) Yihai Cao Nature Reviews Endocrinology
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
- (2014) K M Dodd et al. ONCOGENE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2014) Jean-François Korobelnik et al. OPHTHALMOLOGY
- Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues
- (2014) J. Honek et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study
- (2013) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Angiogenesis and Vascular Functions in Modulation of Obesity, Adipose Metabolism, and Insulin Sensitivity
- (2013) Yihai Cao Cell Metabolism
- Adipose Vascular Endothelial Growth Factor Regulates Metabolic Homeostasis through Angiogenesis
- (2013) Hoon-Ki Sung et al. Cell Metabolism
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
- (2013) Alicia S Chung et al. NATURE MEDICINE
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
- (2013) David M. Brown et al. OPHTHALMOLOGY
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
- (2013) Y. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
- (2013) V. T. Phan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
- (2013) Hala Ahmadieh et al. Biomed Research International
- Aging, Cellular Senescence, and Cancer
- (2012) Judith Campisi Annual Review of Physiology
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Ziv-aflibercept: binding to more than VEGF-A—does more matter?
- (2012) Jeffrey M. Clarke et al. Nature Reviews Clinical Oncology
- Antiangiogenic therapy—evolving view based on clinical trial results
- (2012) Gordon C. Jayson et al. Nature Reviews Clinical Oncology
- Diabetic Retinopathy
- (2012) David A. Antonetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion
- (2012) Rohit Varma et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs
- (2012) E.-M. E. Hedlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Angiogenesis for Treating Cardiovascular Diseases
- (2012) Lorenzo Deveza et al. Theranostics
- Elevated membrane attack complex in human choroid with high risk complement factor H genotypes
- (2011) Robert F. Mullins et al. EXPERIMENTAL EYE RESEARCH
- The burden of disease of retinal vein occlusion: review of the literature
- (2011) M Laouri et al. EYE
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
- (2011) Seth B. Coffelt et al. JOURNAL OF IMMUNOLOGY
- Thyroid Dysfunction from Antineoplastic Agents
- (2011) O.-P. R. Hamnvik et al. JNCI-Journal of the National Cancer Institute
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RESTORE Study
- (2011) Paul Mitchell et al. OPHTHALMOLOGY
- Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice
- (2011) A. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Forty-Year Journey of Angiogenesis Translational Research
- (2011) Y. Cao et al. Science Translational Medicine
- PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
- (2010) Carlos Bais et al. CELL
- Lymphangiogenesis: Molecular Mechanisms and Future Promise
- (2010) Tuomas Tammela et al. CELL
- Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate–resistant patients: recommendations and evidence
- (2010) J. Younus et al. Current Oncology
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic DLL4 blockade induces vascular neoplasms
- (2010) Minhong Yan et al. NATURE
- Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy
- (2010) Napoleone Ferrara NATURE MEDICINE
- Off-tumor target—beneficial site for antiangiogenic cancer therapy?
- (2010) Yihai Cao Nature Reviews Clinical Oncology
- Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
- (2010) Yihai Cao NATURE REVIEWS DRUG DISCOVERY
- Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
- (2010) David M. Brown et al. OPHTHALMOLOGY
- Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
- (2010) Y. Cao et al. Science Translational Medicine
- Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6
- (2010) YOSHIKO AOYAGI et al. Oncology Letters
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- Why are tumour blood vessels abnormal and why is it important to know?
- (2009) J A Nagy et al. BRITISH JOURNAL OF CANCER
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- (2009) Johannes Lammer et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation
- (2009) Yuan Xue et al. Cell Metabolism
- Tumor angiogenesis and molecular targets for therapy
- (2009) Yihai Cao Frontiers in Bioscience-Landmark
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
- (2009) E.-M. Hedlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
- (2009) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
- (2009) Y. Cao Science Signaling
- VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis
- (2008) G Thurston et al. BRITISH JOURNAL OF CANCER
- Molecular and developmental biology of the hemangioblast
- (2008) Jing-Wei Xiong DEVELOPMENTAL DYNAMICS
- Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing
- (2008) U. Berchner-Pfannschmidt et al. EUROPEAN RESPIRATORY JOURNAL
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
- (2008) Tuomas Tammela et al. NATURE
- HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
- (2008) Zoltan Arany et al. NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
- Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
- (2008) Y. Xue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
- (2008) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- White Fat Progenitor Cells Reside in the Adipose Vasculature
- (2008) W. Tang et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started